[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 18, 1983

MRFIT and the Oslo Study

Author Affiliations

From the Oslo Study Research Group, Oslo.

JAMA. 1983;249(7):893-894. doi:10.1001/jama.1983.03330310023019
Abstract

THE LARGE American three-factor1 and the much smaller Norwegian two-factor2 coronary heart disease (CHD) prevention trials have come out with different results, the former ending inconclusively, the latter with a significantly reduced incidence of total cardiovascular and CHD end points, and substantial, although nonsignificant, reductions in CHD and total mortality.

The Oslo diet-smoking trial in 1,232 high-risk, normotensive, healthy men aged 40 to 49 years, representing the 20% upper risk of a screened male population of 16,200, combined lipid-lowering dietetic intervention with smoking cessation advice. The trial lasted from five to 6 1/2 years.

Differences Between the Trials  There are two main differences in study design between the two trials. The Multiple Risk Factor Intervention Trial (MRFIT) combined hygienic-dietetic intervention measures against smoking and eating habits with drug treatment of the hypertensive subjects (almost two thirds of the intervention group), while the Oslo Study management decided to exclude

×